2-[3-ethyl-5-[3-[(Z)-prop-1-enyl]iminoprop-1-en-2-yl]-2,4-dihydropyrrol-3-yl]-N-methylethanamine
C15H25N3 — CID 170210096
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[3-ethyl-5-[3-[(Z)-prop-1-enyl]iminoprop-1-en-2-yl]-2,4-dihydropyrrol-3-yl]-N-methylethanamine
2-[3-ethyl-5-[3-[(Z)-prop-1-enyl]iminoprop-1-en-2-yl]-2,4-dihydropyrrol-3-yl]-N-methylethanamine (PubChem CID 170210096) has the molecular formula C15H25N3 and a molecular weight of 247.39 g/mol. Its IUPAC name is 2-[3-ethyl-5-[3-[(Z)-prop-1-enyl]iminoprop-1-en-2-yl]-2,4-dihydropyrrol-3-yl]-N-methylethanamine.
Molecular Properties
| Compound Name | 2-[3-ethyl-5-[3-[(Z)-prop-1-enyl]iminoprop-1-en-2-yl]-2,4-dihydropyrrol-3-yl]-N-methylethanamine |
|---|---|
| PubChem CID | 170210096 |
| Molecular Formula | C15H25N3 |
| Molecular Weight | 247.39 g/mol |
| Exact Mass | 247.20 |
| IUPAC Name | 2-[3-ethyl-5-[3-[(Z)-prop-1-enyl]iminoprop-1-en-2-yl]-2,4-dihydropyrrol-3-yl]-N-methylethanamine |
| SMILES | C=C(/C=N/C=C\C)C1=NCC(CC)(CCNC)C1 |
| InChI | InChI=1S/C15H25N3/c1-5-8-17-11-13(3)14-10-15(6-2,12-18-14)7-9-16-4/h5,8,11,16H,3,6-7,9-10,12H2,1-2,4H3/b8-5-,17-11+ |
| InChIKey | ISGIKEBSZSSNHE-YMZVDNRMSA-N |
| XLogP | 3.00 |
| TPSA | 36.75 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 18 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 247.39 |
| LogP ≤ 5 | 3.00 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 3 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'imine_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 170210096 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.